Cargando…

A phase II dose-ranging study of mirabegron in patients with overactive bladder

INTRODUCTION AND HYPOTHESIS: Mirabegron is a potent and selective β(3)-adrenoceptor agonist that may represent an alternative treatment option in place of antimuscarinics for patients with overactive bladder. METHODS: Patients completed a single-blinded, 2-week placebo run-in period followed by 12 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Chapple, Christopher R., Dvorak, Vladimir, Radziszewski, Pjotr, Van Kerrebroeck, Philip, Wyndaele, Jean Jacques, Bosman, Brigitte, Boerrigter, Peter, Drogendijk, Ted, Ridder, Arwin, Van Der Putten-Slob, Ingrid, Yamaguchi, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3745617/
https://www.ncbi.nlm.nih.gov/pubmed/23471546
http://dx.doi.org/10.1007/s00192-013-2042-x